Homes in Lenawee County sold for higher prices in April. Here's how much
The median home sold for $210,000, an analysis of data from Realtor.com shows. That means April, the most recent month for which figures are available, was up 3.4% from March.
Compared to April 2024, the median home sales price was up 6.1% compared to $197,900.
Realtor.com sources sales data from real estate deeds, resulting in a few months' delay. The statistics don't include homes currently listed for sale and aren't directly comparable to listings data.
Information on your local housing market, along with other useful community data, is available at data.lenconnect.com.
Looking only at single-family homes, the $190,875 median selling price in Lenawee County was down 4.6% in April from $200,000 the month prior. Since April 2024, the sales price of single-family homes was up 2.4% from a median of $186,500. Five single-family homes sold for $1 million or more during the month, compared to one recorded transactions of at least $1 million in April 2024.
Condominiums and townhomes decreased by 22.8% in sales price during April to a median of $297,375 from $385,000 in March. Compared to April 2024, the sales price of condominiums and townhomes was slightly up from $295,500. Eight condominiums or townhomes sold for $1 million or more during the month, compared to zero recorded transactions of $1 million in April 2024.
In April, the number of recorded sales in Lenawee County dropped by 22.6% since April 2024 — from 133 to 103. All residential home sales totaled $57.5 million.
Across Michigan, homes sold at a median of $240,030 during April, up 3.2% from $232,607 in March. There were 10,478 recorded sales across the state during April, down 4.1% from 10,921 recorded sales in April 2024.
The total value of recorded residential home sales in Michigan increased by 24.2% from $2.6 billion in March to $3.2 billion this April.
Of all residential home sales in Michigan, 1.73% of homes sold for at least $1 million in April, up from 1.24% in April 2024.
Sales prices of single-family homes across Michigan increased by 1.3% from a median of $223,997 in March to $226,875 in April. Since April 2024, the sales price of single-family homes across the state was up 3.6% from $218,905.
Across the state, the sales price of condominiums and townhomes rose 6.6% from a median of $294,762 in March to $314,295 during April. The median sales price of condominiums and townhomes is up 13.3% from the median of $277,375 in April 2024.
The median home sales price used in this report represents the midway point of all the houses or units listed over the given period of time. The median offers a more accurate view of what's happening in a market than the average sales price, which would mean taking the sum of all sales prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high sale.
The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Realtor.com. Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI Team would like to hear from you. Take this survey and share your thoughts with us.
This article originally appeared on The Daily Telegram: Homes in Lenawee County sold for higher prices in April. Here's how much
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Universal Music Group Files Confidentially for US Listing
(Bloomberg) -- Universal Music Group NV has filed confidentially for a US listing, which would fulfill the terms of a deal with billionaire Bill Ackman's hedge fund Pershing Square. Why the Federal Reserve's Building Renovation Costs $2.5 Billion Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Milan Corruption Probe Casts Shadow Over Property Boom How San Jose's Mayor Is Working to Build an AI Capital The Amsterdam-listed firm submitted documents to the US Securities & Exchange Commission relating to a proposed offering by certain of its shareholders, according to a statement Monday. The world's largest music company won't receive any proceeds from the sale. Universal Music's shares rose 0.9% to €27.31 apiece at 9:51 a.m. in European trading on Tuesday, leading gains in Amsterdam's AEX Index. The filing comes after Universal said in January it would plan the US listing in order to satisfy an agreement with Pershing Square, a statement at the time showed. Ackman resigned from Universal's board in May, citing increasing demands on his time from commitments including his appointment as Executive Chairman of Howard Hughes Holdings Inc. Universal Music, which is the label for artists including Taylor Swift, had in recent months resisted Ackman's push to move its domicile and delist it from Euronext Amsterdam. Pershing Square had urged Universal Music to pursue a US listing, saying it would substantially increase the valuation of the shares. A group of shareholders affiliated with Pershing Square in March raised more than €1.3 billion ($1.5 billion) from the sale of about a 2.7% stake in the Hilversum, Netherlands-headquartered firm, Bloomberg News reported. --With assistance from Sarah Jacob. (Updates with share move in third paragraph.) Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All What the Tough Job Market for New College Grads Says About the Economy ©2025 Bloomberg L.P.
Yahoo
20 minutes ago
- Yahoo
Telix Reports $204M Revenue, Up 63% YOY
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise. Q2 2025 Highlights Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year. FY 2025 revenue guidance of $770 million to $800 million is reaffirmed. Gozellix® launched in the U.S. and commercial dose deliveries commenced. Gozellix has been assigned a Level II HCPCS code1 (effective 1 October 2025), a prerequisite for receiving Transitional Pass-Through payment status. ProstACT™ Global Phase 3 trial milestone – all 30 patients consented for Part 1. Global expansion with regulatory approvals to expand the trial into China, Japan and Canada. Q2 2025 Revenue (Unaudited) Revenue$M Q2 2025 Q2 2024 Variation Q1 2025 Variation Group revenue 204 125 63% 186 10% Global Illuccix® revenue 154 123 25% 151 2% RLS revenue1 46 - - 332 39% Commentary and business highlights Dr. Christian Behrenbruch, Managing Director and Group CEO, Telix, stated, 'Dose volumes for Illuccix rose 7% quarter-on-quarter in the U.S., reinforcing the strength of our market position and continued customer demand. Despite emerging competitive pricing pressure, we have effective strategies in place to manage impact to average selling price. This includes the recent launch of Gozellix which has been assigned a HCPCS code, a crucial reimbursement milestone towards pass-through status. We continue to show positive momentum across multiple assets in our therapeutic pipeline, including achievement of a key recruitment milestone in our ProstACT Global Phase 3 trial.' Therapeutics business TLX591 (177Lu-rosopatamab tetraxetan): Telix has consented all 30 patients required to complete Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate. Patients in two of the three arms (abiraterone and enzalutamide as standard of care) have completed dosing. An interim readout of safety and dosimetry will follow the completion of patient dosing, monitoring and data analysis. The trial is proceeding seamlessly into Part 2 at existing ex-U.S. sites and additional regulatory approvals have been obtained to commence the trial in China, Canada and Japan4. TLX592 (225Ac-PSMA-RADmAb): Telix has submitted a Human Research Ethics Committee (HREC) application in Australia for a Phase 1, first-in-human therapeutic study of a targeted alpha therapy in advanced metastatic castration resistant prostate cancer. TLX101 (131I-iodofalan, or 131I-IPA): Telix received HREC approval in Australia to commence IPAX BrIGHT, an international pivotal trial. An IPAX BrIGHT Clinical Trial Application (CTA) has also been submitted in Europe. TLX250 (¹⁷⁷Lu-DOTA-girentuximab): STARLITE-15 is enrolling patients. This Phase 1b/2 clinical trial is investigating the use of TLX250 in combination with cabozantinib and nivolumab, in clear cell renal cell carcinoma (ccRCC). Trial submission is in preparation for a pivotal trial of TLX250 as a monotherapy in advanced metastatic ccRCC, initially launching ex-U.S. TLX090 (¹⁵³Sm-DOTMP): In July, Telix submitted an Investigational New Drug (IND) application for a Phase 1 bridging study for Telix's therapeutic candidate for the palliation of bone pain in patients with osteoblastic metastatic disease to the bone. Precision Medicine businessTelix received country-level approvals for Illuccix in France, Finland, Ireland, Sweden, Germany, Portugal, Greece, the Czech Republic, Belgium and Italy in Q2 and is launching on a market-by-market basis, as reimbursement is secured. Telix has completed enrolment of the Illuccix China Phase 3 study6, which will be used to file a marketing authorization in China in Q4 2025. Telix has received HREC approval in Australia and filed an IND with the FDA in the U.S. for a Phase 3 clinical trial aimed at expanding the label indication for Illuccix and Gozellix. The BiPASS study7 will evaluate the performance of MRI8 combined with PSMA PET9 imaging for detection and diagnosis of prostate cancer, which is designed to reduce the need for invasive biopsies. Telix has submitted a Prior Approval Supplement (PAS) to update the U.S. Prescribing Information for Illuccix. The proposed label expansion includes patient selection for radioligand therapy (RLT) in the pre-taxane setting. The prescribing information is expected to be updated, following FDA's review of the submission10. As part of product lifecycle management strategy, Telix announced a novel PET11 radiochemistry solution based on fluorine-18 (18F)-aluminium fluoride (AlF), branded AlFluor™12. The platform technology enables flexible radiolabeling of PSMA13 with either AlF or gallium-68 (68Ga). As part of the platform's development, Telix signed a strategic agreement with University Hospital Ghent and Ghent University for a novel [18F]AlF-PSMA-11 targeting agent, including extensive clinical data to enable a U.S. registration trial. Pixclara®14 (TLX101-CDx, 18F-floretyrosine or 18F-FET): A successful Type A meeting was held with the FDA on 24 June 2025, to agree on a path forward for resubmitting the New Drug Application (NDA) for Telix's brain cancer imaging candidate. Zircaix®15 (TLX250-CDx, 89Zr-DFO-girentuximab): The Company continues to progress a Biologics License Application (BLA) with the FDA for its kidney cancer PET imaging candidate. The PDUFA16 date remains 27 August 2025. Telix Manufacturing Solutions (TMS) Telix announced its Good Manufacturing Practice (GMP) manufacturing facility in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific region represents a significant milestone in the Company's global manufacturing strategy. It will serve as a hub for commercial and clinical drug product supply, and future research and development in the region. The TMS facility in Brussels South (Seneffe), Belgium, produced its first GMP commercial radiopharmaceutical doses, marking the formal launch of Telix's radiopharmaceutical manufacturing capability in Europe. Corporate update Telix has received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates. The Company is fully cooperating with the SEC and is in the process of responding to the information request. At this stage, this matter is a fact-finding request. The Company has elected to notify the Australian Securities and Investments Commission of the SEC's information request. Telix's policy is not to discuss any details of an ongoing regulatory inquiry. The information request from the SEC does not mean that Telix or anyone else has violated United States federal securities laws or that the SEC has a negative opinion of any person, entity or security. We cannot predict when this matter will be resolved or what (if any) action the SEC may take following the conclusion of this investigation. While the matter is ongoing, Telix will continue with its clinical development programs relating to its prostate cancer therapy candidates, in the ordinary course of business. The information request does not extend to Telix's commercial and late-stage precision medicine products including Illuccix, Gozellix, Zircaix, Pixclara and Scintimun®. FY 2025 guidance Telix confirms FY 2025 revenue guidance of $770 million to $800 million17. Guidance reflects revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS18. Telix confirms research and development (R&D) expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024. Guidance disclaimer The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below. Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix's ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, United Kingdom, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA19, and in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the FDA20. Telix's osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix's miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations (Global)Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Investor Relations (U.S.)Annie KasparianTelix Pharmaceuticals LimitedDirector Investor Relations and Corporate CommunicationsEmail: Media Contact Eliza Schleifstein Eliza@ This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors. Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2025 Telix Pharmaceuticals Limited. All rights reserved. 1 Healthcare Common Procedure Coding System, refer to ASX disclosure 9 July 2025.2 Excludes revenue contribution from Illuccix sales.3 Revenue from date of RLS acquisition 27 January 2025.4 IND approved in China 22 July 2025; Clinical Trial Notification (CTN) approved in Japan 20 June 2025; Clinical Trial Application for Part 2 approved in Canada 22 May 2025.5 ID: NCT05663710.6 Refer to disclosure 13 May 2025.7 ID: NCT07052214.8 Magnetic resonance imaging.9 Imaging of prostate-specific membrane antigen with positron emission tomography.10 Subsequent to Telix disclosure on 23 June 2025, the FDA reclassified the submission to a PAS. The submission was made 5 June 2025.11 Positron Emission Tomography.12 Refer to ASX disclosure 20 June 2025.13 Prostate-specific membrane antigen.14 Brand name subject to final regulatory approval.15 Brand name subject to final regulatory approval.16 Prescription Drug User Fee Act. 17 Refer to ASX disclosures 20 February 2025. 18 See Guidance Disclaimer for further information.19 Telix ASX disclosure 20 December 2021.20 Telix ASX disclosure 21 March 2025.
Yahoo
20 minutes ago
- Yahoo
EV Connector Market worth $8.80 billion by 2032
DELRAY BEACH, Fla., July 22, 2025 /PRNewswire/ -- The EV connector market is projected to reach USD 8.80 billion by 2032, from USD 2.73 billion in 2025, with a CAGR of 18.2%, according to a new report by MarketsandMarkets. EV connectors for high-voltage systems are increasingly required to support miniaturization, weight reduction, and high-performance materials, alongside rising demand for high-bandwidth, low-latency transmission to support complex systems such as ADAS, battery management, vehicle lighting, and autonomous driving. As EVs rapidly adopt advanced driver-assistance and autonomous technologies, connectors must handle massive data flows, offering manufacturers opportunities for technological advancement. This trend is further accelerated by the shift toward zonal architectures and centralized computing, driving demand for multi-signal, high-speed connectors. Download an Illustrative overview: Browse in-depth TOC on "EV Connector Market" 307 - Tables 83 - Figures 305 - Pages Battery management systems are expected to show significant growth during the forecast period As EV battery architectures shift to more integrated, structural formats, demand for precise and reliable connectors has become more pronounced. In January 2024, JAE supplied HVIL-compliant signal connectors for BYD's Blade Battery, meeting high vibration tolerance and enabling stable BMS-to-cell communication. Similarly, in March 2024, TE Connectivity launched AMP+ high-voltage connectors for compact BMS setups in cylindrical and prismatic cells, offering enhanced creepage, clearance, and EMI shielding. These connectors featured improved creepage and clearance characteristics along with integrated shielding to minimize EMI, ensuring robust signal and power transmission in high-vibration environments. Such developments highlight a growing emphasis on connector precision and reliability as essential enablers of high-performance and safety-centric battery management systems in next-generation EVs. Board-to-board connection is expected to hold the largest share during the forecast period Board-to-board connectors establish direct electrical connections between two printed circuit boards (PCBs) within the same electronic module. These connectors support vertical, horizontal, and mezzanine stacking and are critical in applications such as digital cockpit units, centralized computing systems, and battery control modules. Their key advantages include enabling modular design, minimizing signal loss, and supporting high-speed data transmission in software-defined vehicle architectures. In June 2024, ERNI introduced zero-insertion-force board-to-board connectors for modular stacked ECU applications such as ADAS, infotainment, zonal architectures, and autonomous driving controllers, supporting multi-row layouts and shielded designs. Asia Pacific is expected to be the leading market during the forecast period Asia Pacific leads the global EV connector market, driven by robust manufacturing capabilities, increased EV production, and rapid innovation in vehicle electronics. As of 2024, the region accounted for over 55% of global EV output, supported by key automakers such as BYD, SAIC, Geely, Toyota, Hyundai, and Tata Motors. This strong presence fuels consistent demand for a broad spectrum of connectors from high-voltage components used in batteries and traction inverters to compact signal connectors for infotainment, ADAS, and zonal control systems in software-defined vehicles (SDVs). In July 2024, Sumitomo Electric began developing fiber-optic connectors to enable high-speed data transfer in SDVs through zonal E/E architectures. Adding to the region's momentum, Hyundai Mobis expanded its EV components plant in Ulsan in June 2024 to scale production of integrated connector modules, reinforcing Asia Pacific's position as the strategic hub for next-generation EV connector development. Key Market EV Connector Industry: Prominent players in the EV Connector Companies include as TE Connectivity Ltd. (Ireland), Aptiv (Ireland), Yazaki Corporation (Japan), Molex (US), and Hirose Electric Co., Ltd. (Japan), among others. Get 10% Free Customization on this Report: This report provides insights on: Analysis of key drivers (OEMs' emphasis on electrification of mid-segment and luxury vehicles, Rapid integration of ADAS and safety systems, Consumer preference for seamless and interactive driving experience), restraints (Volatility in Raw Material Prices), opportunities (Scaling of autonomous driving technologies, Shift toward advanced electrical/electronic (E/E) architecture), and challenges (Material degradation due to mechanical wear and thermal stresses, Transition from conventional connector systems to modular platform designs) influencing the growth of the EV connector market Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the EV connector market Market Development: Comprehensive information about lucrative markets – the report analyses the EV connector market across various regions Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the EV connector market Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like TE Connectivity (Ireland), Aptiv (Ireland), Yazaki Corporation (Japan), Molex (US), and Hirose Electric Co., Ltd. (Japan) in the EV connector market. Related Reports: Electric Vehicle Market EV Charging Station Market EV Cables Market Get access to the latest updates on EV Connector Companies and EV Connector Industry Growth About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
